aluates Reports

$ 0.0

Automative

Global Targeted Drugs for NSCLC Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-16D5972

Global Targeted Drugs for NSCLC Market Insights and Forecast to 2028

BUY CHAPTERS

Global Targeted Drugs for NSCLC Market Research Report 2025

Code: QYRE-Auto-16D5972

Report

September 2025

Pages:107

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Allergan plc

Amgen Inc

ARIAD Pharmaceuticals (Takeda)

Beacon Pharma Limited

BeiGene Ltd

Biocon Ltd.

Boehringer Ingelheim

Celgene Corporation

Drug International Limted

Fujifilm Kyowa Kirin Biologics

Genvio Pharma Limited

Hetero Drugs

ImClone Systems ‎(Eli Lilly)

Incepta Pharmaceuticals

Mylan NV

Novartis

Pfizer Inc

Reliance lifesciences

Roche

Astrazeneca plc

Cipla Ltd

TEVA

OSI Pharmaceuticals

Glenmark Pharmaceuticals

Natco Pharma

Targeted Drugs for NSCLC Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Targeted Drugs for NSCLC Market

The global market for Targeted Drugs for NSCLC was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for NSCLC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for NSCLC.

The Targeted Drugs for NSCLC market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drugs for NSCLC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Targeted Drugs for NSCLC companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Targeted Drugs for NSCLC Market Report

Report Metric	Details
Report Name	Targeted Drugs for NSCLC Market
CAGR	5%
Segment by Type	Target EGFR Target ALK Target HER2 Target ROS1 Target BRAF Target MEK Target VEGFR2 Target VEGF Target MET
Segment by Application	Squamous Cell Carcinoma of NSCLC Adenocarcinoma of NSCLC Large Cell Carcinoma of NSCLC
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Allergan, Amgen, ARIAD Pharmaceuticals (Takeda), Beacon Pharma Limited, BeiGene, Biocon, Boehringer-Ingelheim, Celgene Corporation, Drug International Limted, Fujifilm Kyowa Kirin Biologics, Genvio Pharma Limited, Hetero Drugs, ImClone Systems ‎(Eli Lilly), Incepta Pharmaceuticals, Mylan, Novartis, Pfizer, Reliance Lifesciences, Roche, AstraZeneca, Cipla, Teva, OSI Pharmaceuticals, Glenmark Pharmaceuticals, Natco Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for NSCLC company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drugs for NSCLC Market report?

Ans: The main players in the Targeted Drugs for NSCLC Market are Allergan, Amgen, ARIAD Pharmaceuticals (Takeda), Beacon Pharma Limited, BeiGene, Biocon, Boehringer-Ingelheim, Celgene Corporation, Drug International Limted, Fujifilm Kyowa Kirin Biologics, Genvio Pharma Limited, Hetero Drugs, ImClone Systems ‎(Eli Lilly), Incepta Pharmaceuticals, Mylan, Novartis, Pfizer, Reliance Lifesciences, Roche, AstraZeneca, Cipla, Teva, OSI Pharmaceuticals, Glenmark Pharmaceuticals, Natco Pharma

What are the Application segmentation covered in the Targeted Drugs for NSCLC Market report?

Ans: The Applications covered in the Targeted Drugs for NSCLC Market report are Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC

What are the Type segmentation covered in the Targeted Drugs for NSCLC Market report?

Ans: The Types covered in the Targeted Drugs for NSCLC Market report are Target EGFR, Target ALK, Target HER2, Target ROS1, Target BRAF, Target MEK, Target VEGFR2, Target VEGF, Target MET

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Target EGFR

1.2.3 Target ALK

1.2.4 Target HER2

1.2.5 Target ROS1

1.2.6 Target BRAF

1.2.7 Target MEK

1.2.8 Target VEGFR2

1.2.9 Target VEGF

1.2.10 Target MET

1.3 Market by Application

1.3.1 Global Targeted Drugs for NSCLC Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Squamous Cell Carcinoma of NSCLC

1.3.3 Adenocarcinoma of NSCLC

1.3.4 Large Cell Carcinoma of NSCLC

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Targeted Drugs for NSCLC Market Perspective (2020-2031)

2.2 Global Targeted Drugs for NSCLC Growth Trends by Region

2.2.1 Global Targeted Drugs for NSCLC Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Targeted Drugs for NSCLC Historic Market Size by Region (2020-2025)

2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Region (2026-2031)

2.3 Targeted Drugs for NSCLC Market Dynamics

2.3.1 Targeted Drugs for NSCLC Industry Trends

2.3.2 Targeted Drugs for NSCLC Market Drivers

2.3.3 Targeted Drugs for NSCLC Market Challenges

2.3.4 Targeted Drugs for NSCLC Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Targeted Drugs for NSCLC Players by Revenue

3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2020-2025)

3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2020-2025)

3.2 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Targeted Drugs for NSCLC Revenue

3.4 Global Targeted Drugs for NSCLC Market Concentration Ratio

3.4.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2024

3.5 Global Key Players of Targeted Drugs for NSCLC Head office and Area Served

3.6 Global Key Players of Targeted Drugs for NSCLC, Product and Application

3.7 Global Key Players of Targeted Drugs for NSCLC, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drugs for NSCLC Breakdown Data by Type

4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2020-2025)

4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2026-2031)

5 Targeted Drugs for NSCLC Breakdown Data by Application

5.1 Global Targeted Drugs for NSCLC Historic Market Size by Application (2020-2025)

5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Targeted Drugs for NSCLC Market Size (2020-2031)

6.2 North America Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Targeted Drugs for NSCLC Market Size by Country (2020-2025)

6.4 North America Targeted Drugs for NSCLC Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Targeted Drugs for NSCLC Market Size (2020-2031)

7.2 Europe Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Targeted Drugs for NSCLC Market Size by Country (2020-2025)

7.4 Europe Targeted Drugs for NSCLC Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Targeted Drugs for NSCLC Market Size (2020-2031)

8.2 Asia-Pacific Targeted Drugs for NSCLC Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2020-2025)

8.4 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Targeted Drugs for NSCLC Market Size (2020-2031)

9.2 Latin America Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Targeted Drugs for NSCLC Market Size by Country (2020-2025)

9.4 Latin America Targeted Drugs for NSCLC Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Targeted Drugs for NSCLC Market Size (2020-2031)

10.2 Middle East & Africa Targeted Drugs for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2020-2025)

10.4 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Allergan

11.1.1 Allergan Company Details

11.1.2 Allergan Business Overview

11.1.3 Allergan Targeted Drugs for NSCLC Introduction

11.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.1.5 Allergan Recent Development

11.2 Amgen

11.2.1 Amgen Company Details

11.2.2 Amgen Business Overview

11.2.3 Amgen Targeted Drugs for NSCLC Introduction

11.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.2.5 Amgen Recent Development

11.3 ARIAD Pharmaceuticals (Takeda)

11.3.1 ARIAD Pharmaceuticals (Takeda) Company Details

11.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview

11.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction

11.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development

11.4 Beacon Pharma Limited

11.4.1 Beacon Pharma Limited Company Details

11.4.2 Beacon Pharma Limited Business Overview

11.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction

11.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.4.5 Beacon Pharma Limited Recent Development

11.5 BeiGene

11.5.1 BeiGene Company Details

11.5.2 BeiGene Business Overview

11.5.3 BeiGene Targeted Drugs for NSCLC Introduction

11.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.5.5 BeiGene Recent Development

11.6 Biocon

11.6.1 Biocon Company Details

11.6.2 Biocon Business Overview

11.6.3 Biocon Targeted Drugs for NSCLC Introduction

11.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.6.5 Biocon Recent Development

11.7 Boehringer-Ingelheim

11.7.1 Boehringer-Ingelheim Company Details

11.7.2 Boehringer-Ingelheim Business Overview

11.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction

11.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.7.5 Boehringer-Ingelheim Recent Development

11.8 Celgene Corporation

11.8.1 Celgene Corporation Company Details

11.8.2 Celgene Corporation Business Overview

11.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction

11.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.8.5 Celgene Corporation Recent Development

11.9 Drug International Limted

11.9.1 Drug International Limted Company Details

11.9.2 Drug International Limted Business Overview

11.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction

11.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.9.5 Drug International Limted Recent Development

11.10 Fujifilm Kyowa Kirin Biologics

11.10.1 Fujifilm Kyowa Kirin Biologics Company Details

11.10.2 Fujifilm Kyowa Kirin Biologics Business Overview

11.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction

11.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.10.5 Fujifilm Kyowa Kirin Biologics Recent Development

11.11 Genvio Pharma Limited

11.11.1 Genvio Pharma Limited Company Details

11.11.2 Genvio Pharma Limited Business Overview

11.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction

11.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.11.5 Genvio Pharma Limited Recent Development

11.12 Hetero Drugs

11.12.1 Hetero Drugs Company Details

11.12.2 Hetero Drugs Business Overview

11.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction

11.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.12.5 Hetero Drugs Recent Development

11.13 ImClone Systems ‎(Eli Lilly)

11.13.1 ImClone Systems ‎(Eli Lilly) Company Details

11.13.2 ImClone Systems ‎(Eli Lilly) Business Overview

11.13.3 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Introduction

11.13.4 ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.13.5 ImClone Systems ‎(Eli Lilly) Recent Development

11.14 Incepta Pharmaceuticals

11.14.1 Incepta Pharmaceuticals Company Details

11.14.2 Incepta Pharmaceuticals Business Overview

11.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction

11.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.14.5 Incepta Pharmaceuticals Recent Development

11.15 Mylan

11.15.1 Mylan Company Details

11.15.2 Mylan Business Overview

11.15.3 Mylan Targeted Drugs for NSCLC Introduction

11.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.15.5 Mylan Recent Development

11.16 Novartis

11.16.1 Novartis Company Details

11.16.2 Novartis Business Overview

11.16.3 Novartis Targeted Drugs for NSCLC Introduction

11.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.16.5 Novartis Recent Development

11.17 Pfizer

11.17.1 Pfizer Company Details

11.17.2 Pfizer Business Overview

11.17.3 Pfizer Targeted Drugs for NSCLC Introduction

11.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.17.5 Pfizer Recent Development

11.18 Reliance Lifesciences

11.18.1 Reliance Lifesciences Company Details

11.18.2 Reliance Lifesciences Business Overview

11.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction

11.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.18.5 Reliance Lifesciences Recent Development

11.19 Roche

11.19.1 Roche Company Details

11.19.2 Roche Business Overview

11.19.3 Roche Targeted Drugs for NSCLC Introduction

11.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.19.5 Roche Recent Development

11.20 AstraZeneca

11.20.1 AstraZeneca Company Details

11.20.2 AstraZeneca Business Overview

11.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction

11.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.20.5 AstraZeneca Recent Development

11.21 Cipla

11.21.1 Cipla Company Details

11.21.2 Cipla Business Overview

11.21.3 Cipla Targeted Drugs for NSCLC Introduction

11.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.21.5 Cipla Recent Development

11.22 Teva

11.22.1 Teva Company Details

11.22.2 Teva Business Overview

11.22.3 Teva Targeted Drugs for NSCLC Introduction

11.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.22.5 Teva Recent Development

11.23 OSI Pharmaceuticals

11.23.1 OSI Pharmaceuticals Company Details

11.23.2 OSI Pharmaceuticals Business Overview

11.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction

11.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.23.5 OSI Pharmaceuticals Recent Development

11.24 Glenmark Pharmaceuticals

11.24.1 Glenmark Pharmaceuticals Company Details

11.24.2 Glenmark Pharmaceuticals Business Overview

11.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction

11.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.24.5 Glenmark Pharmaceuticals Recent Development

11.25 Natco Pharma

11.25.1 Natco Pharma Company Details

11.25.2 Natco Pharma Business Overview

11.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction

11.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2020-2025)

11.25.5 Natco Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Allergan plc

Amgen Inc

ARIAD Pharmaceuticals (Takeda)

Beacon Pharma Limited

BeiGene Ltd

Biocon Ltd.

Boehringer Ingelheim

Celgene Corporation

Drug International Limted

Fujifilm Kyowa Kirin Biologics

Genvio Pharma Limited

Hetero Drugs

ImClone Systems ‎(Eli Lilly)

Incepta Pharmaceuticals

Mylan NV

Novartis

Pfizer Inc

Reliance lifesciences

Roche

Astrazeneca plc

Cipla Ltd

TEVA

OSI Pharmaceuticals

Glenmark Pharmaceuticals

Natco Pharma

List of Tables

Table 1. Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Target EGFR

Table 3. Key Players of Target ALK

Table 4. Key Players of Target HER2

Table 5. Key Players of Target ROS1

Table 6. Key Players of Target BRAF

Table 7. Key Players of Target MEK

Table 8. Key Players of Target VEGFR2

Table 9. Global Targeted Drugs for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Targeted Drugs for NSCLC Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Targeted Drugs for NSCLC Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Targeted Drugs for NSCLC Market Share by Region (2020-2025)

Table 13. Global Targeted Drugs for NSCLC Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Targeted Drugs for NSCLC Market Share by Region (2026-2031)

Table 15. Targeted Drugs for NSCLC Market Trends

Table 16. Targeted Drugs for NSCLC Market Drivers

Table 17. Targeted Drugs for NSCLC Market Challenges

Table 18. Targeted Drugs for NSCLC Market Restraints

Table 19. Global Targeted Drugs for NSCLC Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Targeted Drugs for NSCLC Market Share by Players (2020-2025)

Table 21. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2024)

Table 22. Ranking of Global Top Targeted Drugs for NSCLC Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Targeted Drugs for NSCLC Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Targeted Drugs for NSCLC, Headquarters and Area Served

Table 25. Global Key Players of Targeted Drugs for NSCLC, Product and Application

Table 26. Global Key Players of Targeted Drugs for NSCLC, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Targeted Drugs for NSCLC Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2020-2025)

Table 30. Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2026-2031)

Table 32. Global Targeted Drugs for NSCLC Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2020-2025)

Table 34. Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2026-2031)

Table 36. North America Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Targeted Drugs for NSCLC Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2026-2031) & (US$ Million)

Table 51. Allergan Company Details

Table 52. Allergan Business Overview

Table 53. Allergan Targeted Drugs for NSCLC Product

Table 54. Allergan Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 55. Allergan Recent Development

Table 56. Amgen Company Details

Table 57. Amgen Business Overview

Table 58. Amgen Targeted Drugs for NSCLC Product

Table 59. Amgen Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 60. Amgen Recent Development

Table 61. ARIAD Pharmaceuticals (Takeda) Company Details

Table 62. ARIAD Pharmaceuticals (Takeda) Business Overview

Table 63. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product

Table 64. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 65. ARIAD Pharmaceuticals (Takeda) Recent Development

Table 66. Beacon Pharma Limited Company Details

Table 67. Beacon Pharma Limited Business Overview

Table 68. Beacon Pharma Limited Targeted Drugs for NSCLC Product

Table 69. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 70. Beacon Pharma Limited Recent Development

Table 71. BeiGene Company Details

Table 72. BeiGene Business Overview

Table 73. BeiGene Targeted Drugs for NSCLC Product

Table 74. BeiGene Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 75. BeiGene Recent Development

Table 76. Biocon Company Details

Table 77. Biocon Business Overview

Table 78. Biocon Targeted Drugs for NSCLC Product

Table 79. Biocon Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 80. Biocon Recent Development

Table 81. Boehringer-Ingelheim Company Details

Table 82. Boehringer-Ingelheim Business Overview

Table 83. Boehringer-Ingelheim Targeted Drugs for NSCLC Product

Table 84. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 85. Boehringer-Ingelheim Recent Development

Table 86. Celgene Corporation Company Details

Table 87. Celgene Corporation Business Overview

Table 88. Celgene Corporation Targeted Drugs for NSCLC Product

Table 89. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 90. Celgene Corporation Recent Development

Table 91. Drug International Limted Company Details

Table 92. Drug International Limted Business Overview

Table 93. Drug International Limted Targeted Drugs for NSCLC Product

Table 94. Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 95. Drug International Limted Recent Development

Table 96. Fujifilm Kyowa Kirin Biologics Company Details

Table 97. Fujifilm Kyowa Kirin Biologics Business Overview

Table 98. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product

Table 99. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 100. Fujifilm Kyowa Kirin Biologics Recent Development

Table 101. Genvio Pharma Limited Company Details

Table 102. Genvio Pharma Limited Business Overview

Table 103. Genvio Pharma Limited Targeted Drugs for NSCLC Product

Table 104. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 105. Genvio Pharma Limited Recent Development

Table 106. Hetero Drugs Company Details

Table 107. Hetero Drugs Business Overview

Table 108. Hetero Drugs Targeted Drugs for NSCLC Product

Table 109. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 110. Hetero Drugs Recent Development

Table 111. ImClone Systems ‎(Eli Lilly) Company Details

Table 112. ImClone Systems ‎(Eli Lilly) Business Overview

Table 113. ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product

Table 114. ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 115. ImClone Systems ‎(Eli Lilly) Recent Development

Table 116. Incepta Pharmaceuticals Company Details

Table 117. Incepta Pharmaceuticals Business Overview

Table 118. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product

Table 119. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 120. Incepta Pharmaceuticals Recent Development

Table 121. Mylan Company Details

Table 122. Mylan Business Overview

Table 123. Mylan Targeted Drugs for NSCLC Product

Table 124. Mylan Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 125. Mylan Recent Development

Table 126. Novartis Company Details

Table 127. Novartis Business Overview

Table 128. Novartis Targeted Drugs for NSCLC Product

Table 129. Novartis Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 130. Novartis Recent Development

Table 131. Pfizer Company Details

Table 132. Pfizer Business Overview

Table 133. Pfizer Targeted Drugs for NSCLC Product

Table 134. Pfizer Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 135. Pfizer Recent Development

Table 136. Reliance Lifesciences Company Details

Table 137. Reliance Lifesciences Business Overview

Table 138. Reliance Lifesciences Targeted Drugs for NSCLC Product

Table 139. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 140. Reliance Lifesciences Recent Development

Table 141. Roche Company Details

Table 142. Roche Business Overview

Table 143. Roche Targeted Drugs for NSCLC Product

Table 144. Roche Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 145. Roche Recent Development

Table 146. AstraZeneca Company Details

Table 147. AstraZeneca Business Overview

Table 148. AstraZeneca Targeted Drugs for NSCLC Product

Table 149. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 150. AstraZeneca Recent Development

Table 151. Cipla Company Details

Table 152. Cipla Business Overview

Table 153. Cipla Targeted Drugs for NSCLC Product

Table 154. Cipla Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 155. Cipla Recent Development

Table 156. Teva Company Details

Table 157. Teva Business Overview

Table 158. Teva Targeted Drugs for NSCLC Product

Table 159. Teva Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 160. Teva Recent Development

Table 161. OSI Pharmaceuticals Company Details

Table 162. OSI Pharmaceuticals Business Overview

Table 163. OSI Pharmaceuticals Targeted Drugs for NSCLC Product

Table 164. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 165. OSI Pharmaceuticals Recent Development

Table 166. Glenmark Pharmaceuticals Company Details

Table 167. Glenmark Pharmaceuticals Business Overview

Table 168. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product

Table 169. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 170. Glenmark Pharmaceuticals Recent Development

Table 171. Natco Pharma Company Details

Table 172. Natco Pharma Business Overview

Table 173. Natco Pharma Targeted Drugs for NSCLC Product

Table 174. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2020-2025) & (US$ Million)

Table 175. Natco Pharma Recent Development

Table 176. Research Programs/Design for This Report

Table 177. Key Data Information from Secondary Sources

Table 178. Key Data Information from Primary Sources

Table 179. Authors List of This Report

List of Figures

Figure 1. Targeted Drugs for NSCLC Picture

Figure 2. Global Targeted Drugs for NSCLC Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Targeted Drugs for NSCLC Market Share by Type: 2024 VS 2031

Figure 4. Target EGFR Features

Figure 5. Target ALK Features

Figure 6. Target HER2 Features

Figure 7. Target ROS1 Features

Figure 8. Target BRAF Features

Figure 9. Target MEK Features

Figure 10. Target VEGFR2 Features

Figure 11. Target VEGF Features

Figure 12. Target MET Features

Figure 13. Global Targeted Drugs for NSCLC Market Size by Application (2020-2031) & (US$ Million)

Figure 14. Global Targeted Drugs for NSCLC Market Share by Application: 2024 VS 2031

Figure 15. Squamous Cell Carcinoma of NSCLC Case Studies

Figure 16. Adenocarcinoma of NSCLC Case Studies

Figure 17. Large Cell Carcinoma of NSCLC Case Studies

Figure 18. Targeted Drugs for NSCLC Report Years Considered

Figure 19. Global Targeted Drugs for NSCLC Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 20. Global Targeted Drugs for NSCLC Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 21. Global Targeted Drugs for NSCLC Market Share by Region: 2024 VS 2031

Figure 22. Global Targeted Drugs for NSCLC Market Share by Players in 2024

Figure 23. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2024)

Figure 24. The Top 10 and 5 Players Market Share by Targeted Drugs for NSCLC Revenue in 2024

Figure 25. North America Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. North America Targeted Drugs for NSCLC Market Share by Country (2020-2031)

Figure 27. United States Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Canada Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Europe Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Europe Targeted Drugs for NSCLC Market Share by Country (2020-2031)

Figure 31. Germany Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. France Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. U.K. Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Italy Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Russia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Nordic Countries Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Asia-Pacific Targeted Drugs for NSCLC Market Share by Region (2020-2031)

Figure 39. China Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Japan Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. South Korea Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. India Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Australia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Latin America Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Latin America Targeted Drugs for NSCLC Market Share by Country (2020-2031)

Figure 47. Mexico Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Brazil Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Middle East & Africa Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Middle East & Africa Targeted Drugs for NSCLC Market Share by Country (2020-2031)

Figure 51. Turkey Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. UAE Targeted Drugs for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 55. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 56. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 57. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 58. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 59. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 60. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 61. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 62. Drug International Limted Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 63. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 64. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 65. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 66. ImClone Systems ‎(Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 67. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 68. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 69. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 70. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 71. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 72. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 73. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 74. Cipla Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 75. Teva Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 76. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 77. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 78. Natco Pharma Revenue Growth Rate in Targeted Drugs for NSCLC Business (2020-2025)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Targeted Drug ALK Inhibitors for NSCLC Market Research Report 2024

Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Research Report 2024

Global Targeted Drug BRAF Inhibitors for NSCLC Market Research Report 2024

Global Targeted Drug HER2 Inhibitors for NSCLC Market Research Report 2024

Global Targeted Drug MEK Inhibitors for NSCLC Market Research Report 2024

Global Targeted Drugs for Breast Cancer Market Research Report 2024

Drugs for Non Small Cell Lung Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drug ROS1 Inhibitors for NSCLC Market Research Report 2024

Non Small Cell Lung Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lung Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lung Cancer Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Research Report 2024

Global Gynecological Cancers Drug Market Research Report 2025

Global Squamous Non Small Cell Lung Cancer Therapeutics Market Research Report 2025

Lung Cancer Treatment Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global ER Targeted Drugs for Breast Cancer Market Research Report 2024

Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global VEGF Targeted Drugs for Breast Cancer Market Research Report 2024

Global Personalized Medicine for Cancer Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions